Full-Time

Senior Accountant II

Posted on 3/12/2025

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

No salary listed

Senior

Company Does Not Provide H1B Sponsorship

London, UK

Hybrid-eligible role; work remotely up to two days per week.

Category
Cost Accounting
Financial Accounting
Financial Analysis
Accounting
Required Skills
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Qualified accountant (ACA/ACCA/CIMA preferred but other financial qualifications will also be considered)
  • Significant experience working in a revenue accounting relevant role
  • A working knowledge and proficiency in US GAAP revenue accounting
  • Excellent technical knowledge of accounting and finance processes
  • Proven communication and influencing skills in working with multiple stakeholders both internal and external
  • Professional attitude with a proactive and flexible approach
  • Established record in managing multiple and competing priorities
  • Excellent Microsoft Office skills including advanced Excel expertise
Responsibilities
  • Build a partnership of trust and open communication with the Revenue Accounting Senior Manager, International Business Partner, the Global Revenue Accounting team and wider International and US corporate stakeholders
  • Perform Revenue Accounting month-end close activities, including but not limited to: Manage the preparation and review of monthly gross to net revenue journal entries, Analysis of gross to net accounts, including discounts, rebates and pharma fees for multiple countries per the contractual agreements, Gross to net account resolution of variances and queries from internal stakeholders, Analysing sales forecast information to determine the best estimates of accruals for discounts, rebates and pharma fees, Manage the preparation and review of revenue recognition journal entries based on contractual agreements, Manage the monthly process of flash (early estimation of revenues), Manage the reconciliation and review of gross to net revenue accounts, Review of 3PL AR reporting and reconciliation to Vertex accounting, Managing revenue accounting systems such as Automated Journal Entry (AJE) system, Revenue Analytics, Interfaces, Oracle EBS and other systems, as a Super User and be able to support the team with any related user-issues in the first instance, Manage the calculations, preparation, review and filing of compliance related declarations and submissions including review and managing the rebate claims/ payments, Train and coach junior members of the team
  • First time accuracy and completion of month end close activities in the region to provide the finance and commercial organisation with value-add timely insight on the revenue accounting implications of new product launches, reimbursement, distribution agreements, new customer contracts and contract extensions
  • Monitoring of reimbursement agreements for appropriate revenue recognition and continued compliance with key terms, including but not limited to supporting commercial team with external reporting requirements, payback and rebate invoicing, forecast alignment
  • Take the lead for allocated markets in region & provide business support to the Country Manager, Finance, Market Access and Commercial teams
  • Manage and run revenue accounting alignment and Key Estimate meetings
  • Be the first point of contact for all revenue related issues. Build and maintain trust with all key stakeholders
  • Support the Revenue Accounting Senior Manager/Business Partner with managing revenue-related activities for all entities in the region
  • Partake in contract reviews, prepare for product launches and translating the contract terms into revenue BAU activities
  • Support the regional finance in terms of local reporting related to revenue/ unit reconciliations to facilitate rebate/ contractual claims
  • Support the treasury team to forecast fund flows for contractual payments in the region
  • Preparation and review of: group reporting requirements for the region, data analysis to support business and accounts reviews, general ledger account analysis and reconciliation of complex gross to net revenue accounts, all month-end close activities for revenue accounting, including SOX compliance and controls, and GL reconciliations preparation and reviews
  • Support internal and external audit requests for SOX, group, and statutory audits. Provide disclosure for SEC quarterly and annual reporting in HFM
  • Drive change across the team, bring experience of simplification and continuous improvement mindset.
Desired Qualifications
  • Master’s degree with a major in Accounting or Finance
  • Big 4 experience is an advantage
  • Work experience in a service driven function with a business partnering focus within a multinational shared service/GBS organization would be an advantage
  • Language skills relevant to the region is an advantage but not essential
  • Oracle R12, OBIEE, HFM and SMART View (Essbase data sources) experience is an advantage
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's partnership with Orna enhances its gene therapy capabilities.
  • Increased investments indicate strong investor confidence in Vertex's growth potential.
  • Vertex's global expansion includes a patient assistance program for Trikafta in South Africa.

What critics are saying

  • Vertex is under investigation for potential securities law violations.
  • Mixed Phase II results for suzetrigine may delay its development.
  • The $1.07 billion Orna partnership could strain resources if unsuccessful.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic biotech partnerships.
  • Vertex's innovative gene-editing therapies target sickle cell disease and beta thalassemia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

MarketBeat
Feb 14th, 2025
JSF Financial LLC Invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

JSF Financial LLC invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

MarketBeat
Jan 17th, 2025
Channel Wealth LLC Invests $716,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Channel Wealth LLC invests $716,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Zenopa
Jan 8th, 2025
Vertex and Orna Partner for Innovative Gene Therapy Solutions

In a significant advancement for the biopharma industry, Vertex Pharmaceuticals has announced a partnership with Orna Therapeutics to develop cutting-edge in vivo gene editing therapies targeting sickle cell disease and beta thalassaemia.

Pipeline Review
Jan 8th, 2025
Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

We look forward to partnering with Vertex to develop transformative therapies for SCD and TDT, while simultaneously advancing our lead panCAR(TM) pipeline programs in autoimmune and oncology.

Precision Medicine Online
Jan 7th, 2025
Vertex Gains Rights to Orna Therapeutics' Drug Delivery Tech in $1.07B Deal

NEW YORK - Orna Therapeutics on Tuesday said it has inked a deal with Vertex Pharmaceuticals valued at more than $1.07 billion, in which Vertex will use its drug delivery technology to develop new gene-editing treatments for patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).